Health groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monopolies, like the one held by Roche for the spinal muscular atrophy drug Risdiplam, restrict access to affordable medication. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
